

DAFTAR PUSTAKA

- Aal, E.A., Omar, N., Zaghla, H. & Taha, H.E.A.E.T.N.A., Baisiuni, A.A. 2007. Role Of Gamma Glutamyl Transferase In Patients With Chronic Hepatitis C Virus Infection. *Tanta Medical Journal*, Vol. 35 Supp.(April): s399–s406.
- AKA, Noreldin., AS, Mohamed., AH, Abdelaziz. & GAM, Ali. 2015. Correlation between Liver Function Tests and Polymerase Chain Reaction in Chronic Hepatitis C Patients. *J Hepatol Gastroint Dis*, 01(01): 1–11.
- Alhawaris. 2019. Hepatitis C: Epidemiologi, Etiologi, dan Patogenitas. *Jurnal Sains dan Kesehatan*, 2(2): 139–150.
- Ali, N. & Siddiqui, A. 1995. Interaction of polypyrimidine tract-binding protein with the 5' noncoding region of the hepatitis C virus RNA internal initiation of translation. *J.Virol.*, 69(10): 6367–6375.
- Allia, N., Setiawan, P.B. & Soelistijo, S.A. 2021. Correlation Between Hcv Rna Viral Load and Homa-Ir in Chronic Hepatitis C Patients. *Current Internal Medicine Research and Practice Surabaya Journal*, 2(2): 29.
- Al Swaff, R. 2012. Correlation between alanine aminotransferase level, HCV-RNA titer and fibrosis stage in chronic HCV genotype 4 infection. *Egyptian Journal of Medical Human Genetics*, 13(2): 207–212. <http://dx.doi.org/10.1016/j.ejmhg.2012.03.001>.
- Anand, B.S. & Velez, M. 2004. Assessment of correlation between serum titers of hepatitis C virus and severity of liver disease. *World J Gastroenterol*, 10(16): 2409–2411.
- Andrade, R.J., Aithal, G.P., Björnsson, E.S., Kaplowitz, N., Kullak-Ublick, G.A., Larrey, D. & Karlsen, T.H. 2019. EASL Clinical Practice Guidelines: Drug-induced liver injury. *J Hepatol*, 70(6): 1222–1261.
- Argentini, C., Genovese, D., Dettori, S. & Rapicetta, M. 2009. HCV genetic variability: From quasispecies evolution to genotype classification. *Future Microbiol.*, 4(3): 359–373.
- Aryati. 2010. Diagnosis Molekul dan Aplikasi dalam Pengobatan Hepatitis B dan C. *Indonesian Journal of Clinical Pathology and Medical Laboratory*, 16(2): 88–92.
- Bacon, B.R. 2015. Harrison's: Principle of Internal Medicine. In: Kasper, D.L., Hauser, S.L., Longo, D.L., Isselbacher, K.J., Wilson, J.D., Martin, J.B., Fauci, A.S., editors, *Chirrosis and It's Complications*. 19thed., Mc Graw-Hill Education, New York.
- Bagaglio, S., Messina, E., Hasson, H., Galli, A., Uberti-Foppa, C. & Morsica, G. 2019. Geographic distribution of HCV-GT3 subtypes and naturally occurring resistance associated substitutions. *Viruses*, 11: 1–15.
- Bandiera, S., Billie Bian, C., Hoshida, Y., Baumert, T.F. & Zeisel, M.B. 2016. Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma. *Curr Opin Virol*, 20: 99–105.
- Bartenschlager, R. & Lohmann, V. 2000. Replication of hepatitis C virus. *Journal of General Virology*, 81(7): 1631–1648.
- Bashir, M.F., Haider, M.S., Rashid, N. & Riaz, S. 2013. Association of Biochemical Markers, Hepatitis C Virus and Diabetes Mellitus in Pakistani Males. *Trop J*

- Pharm Res*, 12(5): 845–850.
- Bisen, P.S., Prasad, G.B.K.S., Debnath, M. 2010. *Molecular Diagnostics: Promises and Possibilities*. Springer, London.
- Botros, M. & Sikaris, K.A. 2013. The De Ritis Ratio : The test of time The De Ritis Ratio : The Test of Time. *Clin Biochem Rev*, 34(11): 117–130.
- Cahyono, S.B. 2011. Evaluation of Increased Serum Aminotransferase Level in Asymptomatic Patient. *The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy*, 12(2): 109–115.
- Chak, E., Talal, A.H., Sherman, K.E., Schiff, E.R. & Saab, S. 2011. Hepatitis C virus infection in USA: An estimate of true prevalence. *Liver International*, 31(8): 1090–1101.
- Chen, S.L. & Morgan, T.R. 2006. The natural history of hepatitis C virus (HCV) infection. *Int. J. Med. Sci.*, 3(2): 47–52.
- Chevaliez, S. & Pawlotsky, J.M. 2006. Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease. *Int. J. Med. Sci.*, 3(2): 35–40.
- Crawford JW. 2009. Liver & billiary tract. In *Robbins and Cotran Pathologic Basis of Disease, Professional Edition - 8th Edition*. Philadelphia: Saunders.
- Craxi, A. 2014. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. *Journal of Hepatology*, 60(2): 392–420.
- CDC Division of Viral Hepatitis. 2013. Viral Hepatitis Surveillance. pp:1-65
- Dustin, L.B., Bartolini, B., Capobianchi, M.R. & Pistello, M. 2016a. Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy. *Clin Microbiol Infect.*, 22(10): 826–832. Available from: <http://dx.doi.org/10.1016/j.cmi.2016.08.025>.
- Fabris, P., Fleming, V., Giordani, M. & Barnes, E. 2008. Acute Hepatitis C: Clinical Aspects, Diagnosis, and Outcome of Acute HCV Infection. *Curr Pharm D*, 14(17): 1661–1665.
- Ghany, M.G., Strader, D.B., Thomas, D.L. & Seeff, L.B. 2009. Diagnosis, management, and treatment of hepatitis C: An update. *Hepatology*, 49(4): 1335–1374.
- Giannini, E.G., Testa, R. & Savarino, V. 2005. Liver enzyme alteration: A guide for clinicians. *CMAJ*, 172(3): 367–379.
- Gower, E., Estes, C., Blach, S., Razavi-Shearer, K. & Razavi, H. 2014. Global epidemiology and genotype distribution of the hepatitis C virus infection. *J Hepatol*, 61(1 Suppl): S45–S57. Available from: <http://dx.doi.org/10.1016/j.jhep.2014.07.027>.
- Gupta, E., Bajpai, M. & Choudhary, A. 2014. Hepatitis C virus: Screening, diagnosis, and interpretation of laboratory assays. *Asian J Transfus Sci*, 8(1): 19–25.
- Hasan, K.N., Nasrin, F., Taher, M.A., Islam, S., Rahman, O., Jabeen, I., Khaleque, M.A., Akhteruzzaman, S. 2012. Comparative analysis of Hepatitis C Virus (HCV) RNA, Anti-HCV and Liver Transaminase levels as Markers and Predictors of infectivity in HCV infection. *BJMS*, 18(2): 120–125.
- Hiroishi, K., Eguchi, J., Ishii, S., Hiraide, A., Sakaki, M., Doi, H., Omori, R. &

- Imawari, M. 2010. Immune response of cytotoxic T lymphocytes and possibility of vaccine development for hepatitis C virus infection. *J Biomed Biotechnol*, 2010:263810.
- Huang, X.J., Choi, Y.K., Im, H.S., Yarimaga, O., Yoon, E. & Kim, H.S. 2006. Aspartate aminotransferase (AST/GOT) and alanine aminotransferase (ALT/GPT) detection techniques. *Sensors*, 6: 756–782.
- Hurrle, S. & Hsu, W.H. 2017. The etiology of oxidative stress in insulin resistance. *Biomed J*, 40(5): 257–262.
- Jefferies, M., Rauff, B., Rashid, H., Lam, T. & Rafiq, S. 2018. Update on global epidemiology of viral hepatitis and preventive strategies. *World J Clin Cases*, 6(13): 589–599.
- Kemkes RI. 2010. 3% Penduduk dunia terinfeksi hepatitis C, dilihat 10 Mei 2021, Available from: [Kementerian Kesehatan Republik Indonesia \(kemkes.go.id\)](http://kemkes.go.id).
- Kim, W.R., Flamm, S.L., Bisceglie, A.M. Di & Bodenheimer, H.C. 2008. Serum Activity of Alanine Aminotransferase (ALT) as an Indicator of Health and Disease. *Hepatology*, 47(4): 1363–1370.
- Lavanchy, D. 2009. The global burden of hepatitis C. *Liver International*, 29(Suppl 1): 74–81.
- Law, M., editor. 2019. *Hepatitis C Virus Protocols*. Methods in Molecular Biology 1911., Springer Protocols, New York.
- Li, H., Huang, M.H., Jiang, J.D. & Peng, Z.G. 2018. Hepatitis C: From inflammatory pathogenesis to antiinflammatory/hepatoprotective therapy. *World J Gastroenterol*, 24(47): 5297–5311.
- Lingala, S. & Ghany, M.G. 2015. Natural History of Hepatitis C. *Gastroenterol Clin North Am.*, 44(4): 717–734.
- Liu, Z., Que, S., Xu, J. & Peng, T. 2014. Alanine aminotransferase-old biomarker and new concept: A review. *Int. J. Med. Sci.*, 11(9): 925–935.
- Lo, Y.M.D. & Chan, K.C.A. 2006. Introduction to the polymerase chain reaction. In *Methods in Molecular Biology*. 1–9.
- Lok, A.S.F. & Gunaratnam, N.T. 1997. Diagnosis of hepatitis C. *Hepatology*, 26(3 Suppl 1):48S-56S.
- Luedde, T. & Schwabe, R.F. 2011. NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma. *Nat. Rev. Gastroenterol. Hepatol.*, 8(2): 108–118. Available from: <http://dx.doi.org/10.1038/nrgastro.2010.213>.
- Luhmann, N., Champagnat, J., Golovin, S., Maistat, L., Agustian, E., Inaridze, I., Myint, W.M., Butsashvili, M. & Bouscaillou, J. 2015. Access to hepatitis C treatment for people who inject drugs in low and middle income settings: Evidence from 5 countries in Eastern Europe and Asia. *Int J Drug Policy*, 26(11): 1081–1087. Available from: <http://dx.doi.org/10.1016/j.drugpo.2015.07.016>.
- Lukivskaya, O., Zavodnik, L., Knas, M. & Buko, V. 2006. Antioxidant mechanism of hepatoprotection by ursodeoxycholic acid in experimental alcoholic steatohepatitis. *Advances in medical sciences*, 51(May 2014): 54–59.
- Lumongga, F. & Nur Anggraeni, R. 2017. Correlation Between Aspartate Aminotransferase/ Alanine Transferase Ratio (AST/ALT Ratio) and Stage of Liver Fibrosis in Patients with Chronic Hepatitis. *Advanced in Health Sciences*

- Research*, 1(PHICo 2016): 72–75.
- Mangia, A., Schiavone, G., Lezzi, G., Marmo, R., Bruno, F., Villani, M.R., Cascavilla, I., Fantasia, L. & Andriulli, A. 1998. HCV and Diabetes mellitus: Evidence for a negative association. *Am. Coll. of Gastroenterology*, 93(12): 2363–2367.
- Marcellin, P., Asselah, T. & Boyer, N. 2002. Fibrosis and disease progression in hepatitis C. *Jhep*, 36(5 (Suppl 1)): s47–s56.
- Martinot-Peignoux, M., Boyer, N., Cazals-Hatem, D., Pham, B.N., Gervais, A., Breton, V. Le, Levy, S., Degott, C., Valla, D.C. & Marcellin, P. 2001. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. *Hepatology*, 34(5): 1000–1005.
- Maudar, K.K., Gandhi, P., Mishra, P.K., Varshney, S., Punde, R. & Bhargav, A. 2012. Novel Approach for Quantification of Hepatitis C Virus in Liver Cirrhosis Using Real-Time Reverse Transcriptase PCR. *J Gastrointest Surg*, 16: 142–147.
- Mehta, S.H., Brancati, F.L., Sulkowski, M.S., Strathdee, S.A., Szklo, M. & Thomas, D.L. 2001. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. *Hepatology*, 33(6): 1554.
- Mohasin, M., Nila, T., Sultana Tushy, T., Keya, K. & Enamul Haque, M. 2019. Correlation of serum alanine aminotransferase and hepatitis C viral RNA levels in Bangladeshi hepatitis patients Corresponding author. *Bioresearch Communications*, 5(1): 678–683.
- Muljono, D.H. 2017. Epidemiology of hepatitis B and C in Republic of Indonesia. *Euroasian J Hepato-Gastroenterol*, 7(1): 55–59.
- Murray, P.R., Rosenthal, K.S., Pfaller, M.A. 2021. *Medical Microbiology*. 9th ed., Elsevier Inc. USA.
- Mutimer, D., Aghemo, A., Diepolder, H., Negro, F., Robaeys, G., Ryder, S., Zoulim, F., Peck, M., Craxi, A., Fried, M. & Zeuzem, S. 2014. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. *Journal of Hepatology*, 60(2): 392–420.
- Nar, R. & Milletti S.F. 2016. The Relationship Between the Serum RNA Titers of Hepatitis C Virus and Biochemical Parameters in Chronic Hepatitis C Patients. *Viral Hepatit Dergisi*, 22(1): 28–33.
- Núñez, M. 2006. Hepatotoxicity of antiretrovirals: Incidence, mechanisms and management. *J Hepatol*, 44(SUPPL. 1): 132–139.
- Oumaima, S., editor. 2014. Hepatitis C Virus: Molecular Pathways and Treatments. OMICS Group eBooks, USA.
- Özkara, S., Tosun, I., Sari, B., Kiliç, G., Vardar Aker, F., Sezikli, M., Güzelbulut, F. & Bor, E. 2011. The correlation of serum transaminase values with fibrosis staging and necroinflammatory activity scores in chronic hepatitis. *Türkiye Klinikleri Journal of Medical Sciences*, 31(1): 68–74.
- Parmar, K.S., Singh, G.K., Gupta, G.P., Pathak, T., Nayak, S. 2016. Evaluation of De Ritis ratio in liver-associated diseases. *Int J Med Sci Public Health*, 5(9): 1783.
- Pawlotsky, J.M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko,

- G., Marra, F., Puoti, M. & Wedemeyer, H. 2020. EASL recommendations on treatment of hepatitis C: Final update of the series. *Journal of Hepatology*, 73(5): 1170–1218.
- PPHI. 2014. *Konsensus Nasional Penatalaksanaan Hepatitis di Indonesia*. pp:1-16.
- Rebbani, K. & Tsukiyama-kohara, K. 2016. HCV-Induced Oxidative Stress : Battlefield-Winning Strategy. *Oxid Med Cell Longev.*, 2016: 1–7.
- Reid, M., Price, J.C. & Tien, P.C. 2017. Hepatitis C Virus Infection in the Older Patient. *Infect Dis Clin N Am*, 31(4): 827–838.
- RISKESDAS. 2007. Result of National Basic Health Research. pp:223-283
- Romero-Gómez, M., Montagnese, S. & Jalan, R. 2015. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. *J Hepatol*, 62(2): 437–447.
- Roudot-Thoraval, F. 2021. Epidemiology of hepatitis C virus infection. *Clin Res Hepatol Gastroenterol*, 45: 1–6.
- Ruhl, C.E., Menke, A., Cowie, C.C. & Everhart, J.E. 2014. Relationship of hepatitis C virus infection with diabetes in the U.S. population. *Hepatology*, 60(4): 1139–1149.
- Saif-Al-Islam, M., Mohamed, H.S., Younis, M.A., Abdelhamid, M.Y., Ali, M.M. & Khalaf, S. 2020. Impact of Gender Difference on Characteristics and Outcome of Chronic Hepatitis C. *ojgas*, 10(11): 281–294.
- Schiavon, J.L., Schiavon, L.L., Martins, T. 2010. Epidemiology of hepatitis C virus. *Rev Association Med Bras*, 57(1): 105–110.
- Sezer, S., Özdemir, B.H., Arat, Z., Turan, M., Özdemir, N.F. & Haberal, M. 2001. Spectrum of liver damage and correlation with clinical and laboratory parameters in HCV infected hemodialysis patients. *Renal Failure*, 23(6): 807–818.
- Sreedhara H. G, Rudramuneswara Swamy B. P, Mahantesh S, Vijayakumara H. G, R.N.E. 2015. Prevalence of Hepatitis C Virus Infection in Non Insulin Dependent Diabetic Patients (Niddm). *J of Evidence Based Med&Hlthcare*, 2(34): 5269–5278.
- Stasi, C., Silvestri, C. & Voller, F. 2020. Update on Hepatitis C Epidemiology: Unaware and Untreated Infected Population Could Be the Key to Elimination. *SN Compr. Clin. Med.* 2: 2808-2815. Available from: <https://doi.org/10.1007/s42399-020-00588-3>.
- Sy, T. & Jamal, M.M. 2006. Epidemiology of hepatitis C virus (HCV) infection. *Int. J. Med. Sci.*, 3: 41–46.
- Tan, P.O., Mustaffa, N., Tan, S.S. & Lee, Y.Y. 2020. Diagnosis and management of fatty liver. *J R Coll Physicians Edinb*, 50(3): 256–261.
- Vendemiale, G., Grattagliano, I., Portincasa, P., Serviddio, G., Palasciamo, G. & Altomare, E. 2001. Oxidative stress in symptom-free HCV carriers: Relation with ALT flare-up. *Eur J Clin Invest*, 31(1): 54–63.
- Vroon, D. & Israili, Z. 1990. Alkaline Phosphatase and Gamma Glutamyltransferase Clinical Methods: The History, Physical, and Laboratory Examinations. pp: 492–493.
- Wang, H.L., Chu, C.H., Tsai, S.J. & Yang, R.J. 2016. Aspartate aminotransferase and alanine aminotransferase detection on paper-based analytical devices with

- inkjet printer-sprayed reagents. *Micromachines*, 7(1): 1–10.
- Wasley, A. & Alter, M.J. 2000. Epidemiology of hepatitis C: Geographic differences and temporal trends. *Semin Liver Dis*, 20(1): 1–16.
- White, D.L., Ratziu, V. & El-Serag, H.B. 2008. Hepatitis C infection and risk of diabetes: A systematic review and meta-analysis. *J Hepatol*, 49(5): 831–844. <http://dx.doi.org/10.1016/j.jhep.2008.08.006>.
- WHO. 2016. Guidelines for the screening, care and treatment of persons with hepatitis C infection. pp:18-55
- Woreta, T.A. & Alqahtani, S.A. 2014. Evaluation of abnormal liver tests. *Med Clin N Am*, 98(1): 1–16.
- Woyesa, S. & Robinson, A. 2019. Hepatitis C virus infection, genotypes and mechanism of insulin resistance. *J Mol Pathophysiol.*, 8(1): 1–13.
- Xu, R., Huang, H., Zhang, Z. & Wang, F.S. 2014. The role of neutrophils in the development of liver diseases. *Cell Mol Immunol*, 11(3): 224–231. Available from: <http://dx.doi.org/10.1038/cmi.2014.2>.
- Yang, J.H., Lai, J.P., Douglas, S.D., Metzger, D., Zhu, X.H. & Ho, W.Z. 2002. Real-time RT-PCR for quantitation of hepatitis C virus RNA. *J Virol Methods*, 102(1–2): 119–128.
- Zechini, B., Pasquazzi, C. & Aceti, A. 2004. Correlation of serum aminotransferases with HCV RNA levels and histological findings in patients with chronic hepatitis C: The role of serum aspartate transaminase in the evaluation of disease progression. *Eur J Gastroenterol Hepatol.*, 16(9): 891–896.
- Zein, N.N. 2000. Clinical significance of hepatitis C virus genotypes. *Clin. Microbiol. Rev.*, 13(2): 223–235.
- Zhao, L., Daw, M.A. & Shah, K.B. 2014. Hepatitis C Virus: Molecular Pathways and Treatments. *First*, (March): 3–13; 18–26; 27–29.